UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

Journal of hepatology, 2022-01, Vol.76 (1), p.75-85

2022

Volltextzugriff (PDF)

New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Cardiovascular diabetology, 2019-06, Vol.18 (1), p.80-11, Article 80

2019

Volltextzugriff (PDF)

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study

American journal of nephrology, 2019-06, Vol.49 (6), p.470-478

2019

Volltextzugriff (PDF)

Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure

Clinical therapeutics, 2018-03, Vol.40 (3), p.456-468.e1

2018

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants

Naunyn-Schmiedeberg's archives of pharmacology, 2024-07, Vol.397 (7), p.4737-4745

2024

Volltextzugriff (PDF)

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial

Journal of lipid research, 2022-07, Vol.63 (7), p.100233-100233, Article 100233

2022

Volltextzugriff (PDF)

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

EClinicalMedicine, 2021-08, Vol.38, p.101020-101020, Article 101020

2021

Volltextzugriff (PDF)

Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC–MS/MS, a novel antimalarial compound

Bioanalysis, 2021-12, Vol.13 (23), p.1761-1777

2021

Volltextzugriff (PDF)

Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study

Acta diabetologica, 2020-07, Vol.57 (7), p.809-818

2020

Volltextzugriff (PDF)

Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)

American journal of nephrology, 2022-06, Vol.53 (5), p.352-360

2022

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

Clinical pharmacology in drug development, 2023-02, Vol.12 (2), p.202-211

2023

Volltextzugriff (PDF)

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Cardiovascular diabetology, 2020-06, Vol.19 (1), p.93-13, Article 93

2020

Volltextzugriff (PDF)

New drugs and clinical trials rules 2019: Changes in responsibilities of the ethics committee

Perspectives in clinical research, 2020-01, Vol.11 (1), p.37-43

2020

Volltextzugriff (PDF)

Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects

Clinical drug investigation, 2018, Vol.38 (1), p.57-65

2018

Volltextzugriff (PDF)

SAT-239 A phase 4, multicenter, open-label, single-arm study to evaluate the safety and efficacy of saroglitazar 4 mg in patients with non-alcoholic fatty liver disease with obesity, type 2 diabetes mellitus, dyslipidemia, or metabolic syndrome

Journal of hepatology, 2024-06, Vol.80, p.S617-S618

2024

Volltextzugriff (PDF)

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

Hepatology (Baltimore, Md.), 2021-10, Vol.74 (4), p.1809-1824

2021

Volltextzugriff (PDF)

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis

Clinical gastroenterology and hepatology, 2021-12, Vol.19 (12), p.2670-2672

2021

Volltextzugriff (PDF)

A validated tool consisting of bedside variables predicts high-risk NASH (HRN) in individuals with type 2 diabetes

Journal of hepatology, 2023-06, Vol.78, p.S649

2023

Volltextzugriff (PDF)

TOP-080 - A validated tool consisting of bedside variables predicts high-risk NASH (HRN) in individuals with type 2 diabetes

Journal of hepatology, 2023-06, Vol.78, p.S649-S649

2023

Volltextzugriff (PDF)

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients

Liver transplantation, 2023-09, Vol.29 (9), p.979-986

2023

Volltextzugriff (PDF)

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

Clinical gastroenterology and hepatology, 2023-09, Vol.21 (10), p.2597-2605.e2

2023

Volltextzugriff (PDF)

Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India

Clinical breast cancer, 2022-06, Vol.22 (4), p.300-307

2022

Volltextzugriff (PDF)

Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021-11, Vol.1185, p.122982-122982, Article 122982

2021

Volltextzugriff (PDF)

A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)

Clinical infectious diseases, 2021-11, Vol.73 (9), p.e2722-e2728

2021

Volltextzugriff (PDF)

Advancing pediatric drug development in South Asia: Current landscape and vision for the future

Indian journal of pharmacology, 2024-07, Vol.56 (4), p.285-289

2024

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(42)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study

Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC–MS/MS, a novel antimalarial compound

Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study

Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

New drugs and clinical trials rules 2019: Changes in responsibilities of the ethics committee

Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects

SAT-239 A phase 4, multicenter, open-label, single-arm study to evaluate the safety and efficacy of saroglitazar 4 mg in patients with non-alcoholic fatty liver disease with obesity, type 2 diabetes mellitus, dyslipidemia, or metabolic syndrome

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis

A validated tool consisting of bedside variables predicts high-risk NASH (HRN) in individuals with type 2 diabetes

TOP-080 - A validated tool consisting of bedside variables predicts high-risk NASH (HRN) in individuals with type 2 diabetes

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India

Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist

A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)

Advancing pediatric drug development in South Asia: Current landscape and vision for the future

Suchergebnisse filtern